You are here: Industry Insights > EAMS

News List

Early risers: life-changing medical scheme given legal revitalisation pharmatimes
February 03, 2022
Boost for patients with life-threatening conditions who require access to medicines not yet authorised for marketing.
Amicus' Pompe disease therapy joins early access scheme pharmatimes
June 10, 2021
Patients with late-stage Pompe disease who are failing to respond to enzyme replacement therapy will now have early access to an alternative treatment option, after Amicus Therapeutics' cipaglucosidase alfa with miglustat was approved for the UK's ...
MHRA extends access to Santhera's DMD drug via the EAMS pharmatimes
June 24, 2020
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed for a further year the Early Access to Medicines Scheme (EAMS) scientific opinion for Santhera's Duchenne muscular dystrophy (DMD) drug idebenone.
Early access to Tecentriq combination granted through EAMS pharmatimes
January 03, 2019
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab), carboplatin and paclitaxel chemotherapy through.
UK patients get early access to Akcea’s volanesorsen pharmatimes
July 20, 2018
Akcea Therapeutics’ volanesorsen will be available to eligible patients in the UK before it is officially licensed in the EU, having been granted entry to the country’s Early Access to Medicines Scheme.
Sanofi’s dupilumab receives EAMS positive scientific opinion from UK MHRA for AD pharmaceutical-technology
March 17, 2017
UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted French pharmaceutical company Sanofi ...